J Bagan1,2, A Peydró3, J Calvo4, M Leopoldo2, Y Jiménez3, L Bagan5. 1. Oral Medicine, University of Valencia, Valencia, Spain. 2. Service of Stomatology and Maxillofacial Surgery, University General Hospital, Valencia, Spain. 3. Oral Medicine, Valencia University, Valencia, Spain. 4. Rheumatology, University General Hospital, Valencia, Spain. 5. Oral Medicine, Universidad Europea Valencia, Valencia, Spain.
Abstract
OBJECTIVE: To describe the clinical characteristics and evolution of our series of medication-related osteonecrosis of the jaws (MRONJ) associated with denosumab in osteoporotic patients. MATERIAL AND METHODS: We present 10 new cases of MRONJ in patients receiving denosumab for osteoporosis. We describe the mean doses of denosumab, previous bisphosphonate intake, and the clinical characteristics associated with the osteonecrosis, such as local contributing factors, symptoms, and evolution after treatment. RESULTS: The mean number of denosumab doses was 3.4 ± 2.2. In 90% of patients, there was a prior history of oral bisphosphonate intake, with a mean duration of 46.78 ± 25.11 months. The most common local factor was dental extraction (6 cases; 60%), and most cases had necrotic bone exposure (9/10, 90%). Sclerosis of the bone was the most common radiographic finding. Stage 1 was the most common ONM stage, found in 80%. 'Cure' after conservative treatments was obtained in 71.4%. CONCLUSIONS: Most of our cases were in the early stages of MRONJ, and the success rate after conservative treatment was high.
OBJECTIVE: To describe the clinical characteristics and evolution of our series of medication-related osteonecrosis of the jaws (MRONJ) associated with denosumab in osteoporoticpatients. MATERIAL AND METHODS: We present 10 new cases of MRONJ in patients receiving denosumab for osteoporosis. We describe the mean doses of denosumab, previous bisphosphonate intake, and the clinical characteristics associated with the osteonecrosis, such as local contributing factors, symptoms, and evolution after treatment. RESULTS: The mean number of denosumab doses was 3.4 ± 2.2. In 90% of patients, there was a prior history of oral bisphosphonate intake, with a mean duration of 46.78 ± 25.11 months. The most common local factor was dental extraction (6 cases; 60%), and most cases had necrotic bone exposure (9/10, 90%). Sclerosis of the bone was the most common radiographic finding. Stage 1 was the most common ONM stage, found in 80%. 'Cure' after conservative treatments was obtained in 71.4%. CONCLUSIONS: Most of our cases were in the early stages of MRONJ, and the success rate after conservative treatment was high.
Authors: P J Voss; D Steybe; P Poxleitner; R Schmelzeisen; C Munzenmayer; H Fuellgraf; A Stricker; W Semper-Hogg Journal: Odontology Date: 2018-04-30 Impact factor: 2.634
Authors: Rodolfo Mauceri; Rita Coniglio; Antonia Abbinante; Paola Carcieri; Domenico Tomassi; Vera Panzarella; Olga Di Fede; Francesco Bertoldo; Vittorio Fusco; Alberto Bedogni; Giuseppina Campisi Journal: Support Care Cancer Date: 2022-03-16 Impact factor: 3.359